|

Endohepatology-Based Reclassification of Treatment Indication in High-Risk MASLD

RECRUITINGSponsored by University Hospital Muenster
Actively Recruiting
SponsorUniversity Hospital Muenster
Started2026-10-05
Est. completion2028-04-01
Eligibility
Age18 Years+
Healthy vol.Accepted

Summary

This prospective observational study evaluates whether endohepatology changes treatment indications in adults at high risk of metabolic dysfunction-associated steatotic liver disease. Non-invasive testing is followed, when indicated, by a single-session endohepatology assessment including EUS-guided shear-wave elastography, portal pressure gradient measurement and liver biopsy. The primary outcome is treatment reclassification compared with the prospectively documented non-invasive assessment.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Age 18 years or older
* Written informed consent
* Suspected MASLD
* At least one predefined risk criterion

Exclusion Criteria:

* No evidence of MASLD
* HIV infection
* Previous organ transplantation or TIPS
* Current resmetirom therapy
* Decompensated cirrhosis
* Vascular liver disease
* Contraindication to endoscopy, sedation, or liver biopsy
* Pregnancy or breastfeeding
* Inability to provide informed consent

Conditions5

Liver DiseaseLiver FibrosisMetabolic Dysfunction-Associated SteatohepatitisMetabolic Dysfunction-Associated Steatotic Liver DiseasePortal Hypertension

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.